Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $5.5552W HIGH $17.44
Volume
189.83 K
Value Traded
691.84 K
Short % Float
3.31%
-13.29%Week
-41.13%1 Month
-34.39%3 Month
-11.65%6 Month
-96.55%5 Year
-99.6%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
52.52 M
EPS (TTM)
-10.57
P/E Ratio
-
Ent. Value
-65.67 M
Total Shares
9.36 M
Float Shares
8.22 M
Insiders
12.22%
Institutions
53.38%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
ACET Catalyst Timeline
Dated clinical, regulatory and corporate events for Adicet Bio, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Adicet Bio, Inc.
355Total events
14Upcoming
59Tier-1 (high impact)
2017 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Topline Readoutprula-celClinical Data
Adicet Bio announced positive safety and efficacy data from Phase 1 study of prula-cel in SLE with or without LN
Systemic Lupus Erythematosus with or without Lupus Nephritissource ↗
◆Topline Readoutprulacabtagene leucelClinical Data
Phase 1 clinical data for prula-cel in SLE with or without lupus nephritis to be reported
systemic lupus erythematosus with or without lupus nephritissource ↗
◆R&D Dayprulacabtagene leucelPresentation
Webcast presentation to discuss prula-cel Phase 1 clinical results
systemic lupus erythematosus with or without lupus nephritissource ↗
●Last Patient Last Visitprula-celTrial
Completion of last patient visit for planned analysis of prula-cel study
systemic lupus erythematosus with or without lupus nephritissource ↗
◆Topline Readoutprula-celClinical Data
Topline data from planned analysis of prula-cel in SLE
systemic lupus erythematosus with or without lupus nephritissource ↗
●R&D Dayprula-celPresentation
Investor webcast upon release of topline data
systemic lupus erythematosus with or without lupus nephritissource ↗
▲IND ClearanceADI-212FiledIND
FDA clears IND application for ADI-212 in mCRPC
metastatic castration-resistant prostate cancer (mCRPC)source ↗
▲IND ClearanceADI-212FiledIND
FDA clearance of IND for ADI-212
metastatic castration-resistant prostate cancersource ↗
●IND SubmissionADI-212FiledIND
Regulatory filing for ADI-212 planned in 3Q 2026
metastatic castration-resistant prostate cancer (mCPRC)source ↗
◆Topline ReadoutADI-212FiledClinical Data
Initial clinical data for ADI-212 in mCRPC
metastatic castration-resistant prostate cancer (mCRPC)source ↗
●NDA SubmissionADI-212FiledRegulatory Filing
Regulatory filing for ADI-212 in mCRPC
metastatic castration-resistant prostate cancersource ↗
◆Topline Readoutprulacabtagene leucelClinical Data
Phase 1 clinical update for prula-cel in LN and SLE (22 patients, ≥6 months follow-up)
lupus nephritis and systemic lupus erythematosussource ↗
◆Timing GuidanceADI-212FiledPresentation
Regulatory filing for ADI-212 in mCRPC
metastatic castration-resistant prostate cancersource ↗
◆Topline Readoutprulacabtagene leucelClinical Data
Phase 1 clinical update for prula-cel in LN and SLE patients
lupus nephritis and systemic lupus erythematosussource ↗
◆Topline Readoutprula-celClinical Data
Phase 1 clinical update for prula-cel in LN and SLE patients
lupus nephritis and systemic lupus erythematosussource ↗
◆Trial InitiationADI-001Trial
Anticipated initiation of Phase 2 pivotal study in Q2 2026
Lupus Nephritis (LN) and/or Systemic Lupus Erythematosus (SLE)source ↗
◆Type B Meetingprula-celFDA Meeting
Request FDA meeting in Q2 2026 to inform pivotal trial design
LN or LN and SLEsource ↗
◆FDA Feedback Receivedprulacabtagene leucelFDA Meeting
FDA interaction to inform potential pivotal trial design for prula-cel
lupus nephritis and systemic lupus erythematosussource ↗
◆Topline Readoutprulacabtagene leucelClinical Data
Phase 1 clinical update for prula-cel in LN and SLE patients anticipated in mid-2026
lupus nephritis and systemic lupus erythematosussource ↗
◆FDA Feedback Receivedprula-celFDA Meeting
FDA interaction to inform potential pivotal trial design for prula-cel
lupus nephritis and systemic lupus erythematosussource ↗
▲FDA Feedback Receivedprula-celFDA Meeting
FDA alignment enabling outpatient dosing for LN and SLE patients
lupus nephritis (LN) and systemic lupus erythematosus (SLE)source ↗
◆Oral PresentationPresentation
Adicet Bio to present at Guggenheim Emerging Outlook: Biotech Summit 2026
◆Timing Guidanceprula-celPresentation
Clinical update expected in 1H 2026
autoimmune diseases (LN, SLE, SSc)source ↗
●IND SubmissionADI-212FiledIND
Regulatory filing for ADI-212 for mCRPC
metastatic castration-resistant prostate cancer (mCRPC)source ↗
◆FDA Feedback ReceivedADI-001FDA Meeting
Planned FDA meeting to discuss potentially pivotal trial design
lupus nephritis (LN) and systemic lupus erythematosus (SLE)source ↗
▲FDA Feedback Receivedprula-celFDA Meeting
FDA alignment to enable outpatient dosing of SLE and LN patients
systemic lupus erythematosus (SLE) and lupus nephritis (LN)source ↗
▲Topline ReadoutADI-001Clinical Data
Positive preliminary data from ADI-001 Phase 1 study in LN and SLE patients
Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)source ↗
▲Enrollment UpdateADI-001Trial
More than 25 clinical sites open for enrollment globally
Autoimmune diseases (LN, SLE, SSc, IIM, SPS, AAV, RA)source ↗
●Oral PresentationADI-001Presentation
Investor webcast to discuss preliminary data
Autoimmune diseasessource ↗
▲Trial InitiationADI-001Trial
Phase 1 program now open for enrollment in additional autoimmune indications
Systemic sclerosis (SSc), idiopathic inflammatory myopathy, stiff person syndrome, anti-neutrophil cytoplasmic autoantibody associated vasculitis, rheumatoid arthritissource ↗
▲Full ResultsADI-001Clinical Data
Positive preliminary safety and efficacy data from Phase 1 trial of ADI-001 in LN and SLE patients
lupus nephritis (LN) and systemic lupus erythematosus (SLE)source ↗
●Poster PresentationADI-212FiledPresentation
Preclinical data presented at 32nd Annual Prostate Cancer Foundation Scientific Retreat
prostate cancersource ↗
▼Equity OfferingCorporate
Underwritten registered direct offering raised $74.8 million net proceeds
▲First Patient Dosedprula-celTrial
First treatment-refractory RA patient dosed in Phase 1 study
treatment-refractory rheumatoid arthritis (RA)source ↗
▲Topline Readoutprula-celClinical Data
Positive preliminary safety and efficacy data from Phase 1 in LN and SLE
lupus nephritis (LN) and systemic lupus erythematosus (SLE)source ↗
▲Enrollment UpdateADI-001Trial
Enrollment opened for IIM, SPS, and AAV in Phase 1 trial of ADI-001
autoimmune diseases (LN, SLE, SSc, IIM, SPS, AAV)source ↗
▲First Patient DosedADI-001Trial
First SSc patient dosed in Phase 1 trial of ADI-001
systemic sclerosis (SSc)source ↗
◆Topline ReadoutADI-001Clinical Data
Preliminary Phase 1 data for ADI-001 in autoimmune diseases
autoimmune diseasessource ↗
▼Program DiscontinuationADI-270DiscontinuedCorporate
Discontinuation of ADI-270 development and close enrollment
metastatic/advanced clear renal cell carcinoma (ccRCC)source ↗
Past FDA Catalysts and PDUFA Decisions
How ACET actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | prulacabtagene leucel (prula-cel) | Phase 1 topline data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C41 / 100
Pipeline Score
$20M
Pipeline Value
Overvalued
Valuation Signal
3
Drugs Scored
0.4x
rNPV / MCap
Top 35%
Micro Cap(rank 232 of 660)
Percentile Rank
Adicet Bio, Inc. carries a moderate pipeline score (41/100), with $636M risk-adjusted pipeline value, led by ADI-212 in Prostate Cancer Metastatic (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ADI-212 Small moleculeNCT07793435 | Prostate Cancer Metastatic | Phase 1 | NOT YET_RECRUITING | 12 | Oct 1, 2029 |
Clinical Trial Results
Readouts, endpoints and source filings for every ACET program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| prulacabtagene leucel | autoimmune diseases | Phase 1 | 2026-03-13 | strong enrollment progress and the positive data from the prula-cel Phase 1 autoimmune study reported during the fourth quarterRead More | Adicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company ProgressRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P.10% Owner | Other | -250,000 932,624 held | $0.00 | 04/27/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ACET
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 0.1 % | 8.05 M | 1.18 M | 24.72% ( 234.38 K) |
ACET Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ACET ranks across every disease it competes in
Competitive Position is a premium feature
See how ACET ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialACET News
ACET▼ -7%on this news
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Adicet Bio, a biotechnology company, announced the granting of stock options as an inducement award to a new hire. This award, effective September 30, 2026, includes options to purchase 725 shares of common stock. The move reflects the company's ongoing efforts to enhance its workforce and advance its therapeutic developments.
Read more →ACET▼ -29.6%on this newsshared move
Adicet Bio Announces Positive Safety and Efficacy Data from Prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis
Adicet Bio has announced promising safety and efficacy results from its Phase 1 study of prulacabtagene leucel (prula-cel) for treating systemic lupus erythematosus (SLE), including patients with lupus nephritis. The data suggests that prula-cel could be a viable treatment option for this autoimmune condition. The study highlights the potential of Adicet's CAR-T therapies in addressing complex diseases.
Read more →ACET▼ -29.6%on this newsshared move
Adicet Bio to Host Webcast to Present Prula-cel (formerly ADI-001) Clinical Data in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis
Adicet Bio, a clinical-stage biotechnology company, has announced a webcast to present clinical data from its Phase 1 study of prula-cel. This therapy is being evaluated for patients with systemic lupus erythematosus, with or without lupus nephritis. The presentation aims to share insights into the potential of prula-cel as a treatment option.
Read more →ACETAdicet Bio to Participate in Fireside Chat at H.C. Wainwright 28th Annual Global Investment Conference
Adicet Bio, a clinical stage biotechnology company, announced that its CEO, Chen Schor, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference. The event is scheduled to take place from September 14-16, 2026, in New York, showcasing the company's advancements in CAR-T therapies.
Read more →ACET▲ +6.4%on this newsshared move
Adicet Bio Announces Completion of Last Patient Visit for Planned Analysis of prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus With or Without Lupus Nephritis and Provides Corporate Update
Adicet Bio has announced the completion of the last patient visit for its Phase 1 study analyzing the safety and efficacy of prula-cel in patients with systemic lupus erythematosus, with or without lupus nephritis. This milestone marks a significant step in the clinical development of this therapy. The company is focused on advancing treatments for autoimmune diseases.
Read more →ACETAdicet Bio Announces FDA Clearance of IND Application for ADI-212
Adicet Bio has received FDA clearance for its IND application for ADI-212, aimed at treating metastatic castration-resistant prostate cancer. This marks a significant step for the company in developing innovative CAR T cell therapies. The approval allows Adicet to progress its clinical trials for this promising treatment option.
Read more →ACET▼ -13.4%on this news
Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates
Adicet Bio, a clinical stage biotechnology company, reported its financial results for Q2 2026. The company is making progress with its allogeneic gamma delta T cell therapies, particularly prula-cel, with a Phase 1 clinical update expected in Q3 2026. Operational highlights suggest continued advancement in their clinical programs.
Read more →ACET▲ +5.5%on this news
Adicet Bio to Participate in Fireside Chat at Canaccord Genuity 46th Annual Growth Conference
Adicet Bio, a clinical-stage biotechnology company, announced its participation in the Canaccord Genuity 46th Annual Growth Conference. CEO Chen Schor will engage in a fireside chat during the event scheduled for August 11-13, 2026, in Boston. This opportunity highlights the company's focus on developing allogeneic gamma delta T cell therapies.
Read more →ACETAdicet Bio to Participate in Fireside Chat at Jefferies Global Healthcare Conference
Adicet Bio is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference. This event will provide an opportunity for the company to discuss its strategies and developments in the biopharma sector. Further details regarding the timing and specific topics of discussion have not been disclosed.
Read more →ACETAdicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
Adicet Bio has released its financial results for the first quarter of 2026 along with business updates. The report includes insights into the company's performance and future plans. However, specific details regarding financial figures or strategic initiatives were not disclosed in the article.
Read more →ACETAdicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
Adicet Bio reported strong enrollment in its Phase 1 autoimmune program for prulacabtagene leucel, with clinical updates expected in 2026. The company achieved FDA alignment for outpatient dosing in lupus patients. Additionally, a regulatory filing for ADI-212 in metastatic prostate cancer is planned for 2026, with enrollment anticipated to begin later that year.
Read more →ACET▼ -6%on this news
Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Adicet Bio, Inc. will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026. CEO Chen Schor will discuss the company's advancements in allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The event will be accessible via a live audio webcast.
Read more →ACETAdicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones
Adicet Bio has provided a corporate update highlighting important milestones for 2026, including a successful meeting with the FDA to allow outpatient dosing of prulacabtagene leucel for systemic lupus erythematosus (SLE) and lupus nephritis (LN). The company is actively enrolling patients in its Phase 1 autoimmune clinical program, which has expanded to include seven cohorts. Additionally, Adicet plans to submit a regulatory filing for its gene-edited candidate, ADI-212, in 2026, along with further clinical updates expected throughout the year. With a strengthened cash position extending into 2027, Adicet is well-positioned for upcoming pivotal studies.
Read more →ACET▼ -5.4%on this news
Adicet Bio Announces Reverse Stock Split
Adicet Bio, Inc. has announced a one-for-16 reverse stock split to take effect on December 30, 2025. This move aims to help the company regain compliance with Nasdaq's minimum bid price requirement. The split will reduce the outstanding shares from approximately 153.3 million to about 9.6 million, while maintaining the total authorized shares at 300 million.
Read more →ACETAdicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates
Adicet Bio announced positive preliminary safety and efficacy results from its Phase 1 clinical trial of ADI-001 for lupus nephritis (LN) and systemic lupus erythematosus (SLE). The data indicated significant improvements in disease activity and renal function, leading to plans for a pivotal study design meeting with the FDA in early 2026. The company is also actively enrolling patients across various autoimmune diseases for ongoing studies. In addition, Adicet is preparing for a regulatory filing for ADI-212 targeting metastatic castration-resistant prostate cancer and successfully raised $74.8 million in October to support its pipeline.
Read more →ACET▼ -14.7%on this news
Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)
Adicet Bio has announced positive preliminary data from its Phase 1 study of ADI-001 in patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE). All patients experienced significant reductions in disease activity and improved renal function, indicating the therapeutic effectiveness of ADI-001. The treatment was well tolerated, with no serious adverse events noted. Following these promising results, Adicet plans to meet with the FDA in early 2026 to discuss the design of a pivotal Phase 2 trial set to begin mid-2026.
Read more →ACETAdicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates
Adicet Bio reported its financial results for the second quarter of 2025, highlighting active enrollment in multiple clinical trials involving its ADI-001 therapy for autoimmune diseases. The company is on track to share preliminary data in the latter half of 2025 and is also prioritizing the development of ADI-212 for solid tumors. Despite these advancements, Adicet is facing financial pressures, with a reported net loss of $31.2 million, prompting a significant workforce reduction. The company's current cash position is expected to sustain operations through the fourth quarter of 2026.
Read more →ACET▼ -9.4%on this news· ran to -26% by day 1
Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates Two programs with clinical data readouts in 2H/2025
Adicet Bio reported its financial results for Q1 2025, highlighting ongoing clinical trials and program developments. The company is focused on the Phase 1 trials of ADI-001 for autoimmune diseases and ADI-270 for clear cell renal cell carcinoma, with preliminary data expected in the latter half of 2025. Adicet received Fast Track Designation from the FDA for ADI-001 and has expanded its trial enrollment to include systemic lupus erythematosus patients. However, the company registered a slight increase in its net loss compared to the previous year.
Read more →About Adicet Bio, Inc.
Headquarters131 DARTMOUTH STREET, BOSTON, MA, 02116
Founded2014
BIOPHARMAWATCH ELITE PLUS
Trade the next ACET catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime